Delayed
Nasdaq
11:11:36 2024-07-03 am EDT
|
5-day change
|
1st Jan Change
|
2.33
USD
|
+2.64%
|
|
+4.95%
|
-22.07%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
643.2
|
224.5
|
373.7
|
284.4
|
-
|
-
|
Enterprise Value (EV)
1 |
297.5
|
40.03
|
200.2
|
203
|
261.3
|
149.3
|
P/E ratio
|
-8.63
x
|
-3.91
x
|
-5.86
x
|
-3.31
x
|
-2.76
x
|
-2.7
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
1,855
x
|
23.7
x
|
7.34
x
|
EV / Revenue
|
-
|
-
|
-
|
1,325
x
|
21.8
x
|
3.85
x
|
EV / EBITDA
|
-7.16
x
|
-0.77
x
|
-3.22
x
|
-2.33
x
|
-2.76
x
|
-1.53
x
|
EV / FCF
|
-
|
-
|
-
|
-3.15
x
|
-3.32
x
|
-1.75
x
|
FCF Yield
|
-
|
-
|
-
|
-31.7%
|
-30.2%
|
-57.1%
|
Price to Book
|
1.77
x
|
0.71
x
|
1.41
x
|
1.44
x
|
2.41
x
|
3.24
x
|
Nbr of stocks (in thousands)
|
124,167
|
124,724
|
124,969
|
125,265
|
-
|
-
|
Reference price
2 |
5.180
|
1.800
|
2.990
|
2.270
|
2.270
|
2.270
|
Announcement Date
|
2/24/22
|
2/23/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
0.1532
|
11.99
|
38.74
|
EBITDA
1 |
-
|
-41.54
|
-52.02
|
-62.17
|
-87.13
|
-94.65
|
-97.89
|
EBIT
1 |
-
|
-50.5
|
-63.62
|
-76.15
|
-94.39
|
-105.1
|
-106.8
|
Operating Margin
|
-
|
-
|
-
|
-
|
-61,592.56%
|
-876.85%
|
-275.81%
|
Earnings before Tax (EBT)
1 |
-
|
-50.32
|
-57.92
|
-63.68
|
-86.57
|
-105
|
-113.3
|
Net income
1 |
-15.62
|
-50.32
|
-57.92
|
-63.68
|
-86.57
|
-105
|
-113.3
|
Net margin
|
-
|
-
|
-
|
-
|
-56,487.22%
|
-875.94%
|
-292.48%
|
EPS
2 |
-
|
-0.6000
|
-0.4600
|
-0.5100
|
-0.6867
|
-0.8233
|
-0.8400
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-64.4
|
-78.8
|
-85.3
|
FCF margin
|
-
|
-
|
-
|
-
|
-42,022.84%
|
-657.17%
|
-220.2%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/26/21
|
2/24/22
|
2/23/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
0.1532
|
0.725
|
1
|
EBITDA
1 |
-14.02
|
-13.63
|
-12.62
|
-12.64
|
-13.12
|
-14.82
|
-15.48
|
-15.5
|
-16.37
|
-17.98
|
-19.95
|
-20.85
|
-22.55
|
-22.9
|
-23.95
|
EBIT
1 |
-16.82
|
-16.02
|
-15.47
|
-15.82
|
-16.3
|
-18.06
|
-19.02
|
-19.08
|
-20
|
-21.61
|
-22.65
|
-24.15
|
-25.81
|
-25.23
|
-26.95
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-16,841.6%
|
-3,480.28%
|
-2,695%
|
Earnings before Tax (EBT)
1 |
-16.69
|
-15.76
|
-14.69
|
-14.06
|
-13.41
|
-14.96
|
-15.81
|
-15.88
|
-17.02
|
-18.73
|
-20.53
|
-22.17
|
-24.2
|
-25.7
|
-26.7
|
Net income
1 |
-16.69
|
-15.76
|
-14.69
|
-14.06
|
-13.41
|
-14.96
|
-15.81
|
-15.88
|
-17.02
|
-18.73
|
-20.53
|
-22.17
|
-24.2
|
-25.7
|
-26.7
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-15,791.19%
|
-3,544.83%
|
-2,670%
|
EPS
2 |
-0.1300
|
-0.1300
|
-0.1200
|
-0.1100
|
-0.1100
|
-0.1200
|
-0.1300
|
-0.1300
|
-0.1400
|
-0.1500
|
-0.1633
|
-0.1767
|
-0.1900
|
-0.2000
|
-0.2150
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/22
|
5/3/22
|
8/2/22
|
11/1/22
|
2/23/23
|
5/2/23
|
8/2/23
|
10/31/23
|
2/28/24
|
4/30/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
346
|
184
|
173
|
81.3
|
23.1
|
135
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-64.4
|
-78.8
|
-85.3
|
ROE (net income / shareholders' equity)
|
-
|
-30.1%
|
-17.1%
|
-21.9%
|
-36.8%
|
-64.5%
|
-63%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
2.920
|
2.520
|
2.120
|
1.580
|
0.9400
|
0.7000
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
-
|
-
|
2.6
|
2.8
|
2.7
|
Capex / Sales
|
-
|
-
|
-
|
-
|
1,696.57%
|
23.35%
|
6.97%
|
Announcement Date
|
3/26/21
|
2/24/22
|
2/23/23
|
2/28/24
|
-
|
-
|
-
|
Last Close Price
2.27
USD Average target price
4.188
USD Spread / Average Target +84.47% Consensus |
1st Jan change
|
Capi.
|
---|
| -22.07% | 284M | | +16.78% | 44.87B | | -10.52% | 37.8B | | +40.83% | 37.61B | | +28.85% | 31.32B | | -8.44% | 27.4B | | +12.30% | 26.32B | | +41.42% | 14.07B | | +32.54% | 12.5B | | -6.47% | 11.23B |
Other Biotechnology & Medical Research
|